Global Esophageal Cancer Market Research Report- Global Forecast To 2027

Global Esophageal cancer Market Information; By Type (Esophageal Squamous-Cell Carcinoma, Esophageal Adenocarcinoma, Others); By Phases (Phase I, Phases II and Phases III); by Treatment (Surgery, Chemotherapy and radiotherapy and Other) - Forecast to 2027

ID: MRFR/Pharma/2380-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of report has been updated from 2017- 2023 to 2020-2027. Cordially fill Sample form for updated data.

Esophageal Cancer Market Scenario:


Cancer is the leading and second largest cause of death across the globe. The disease is characterized by disordered and deregulated cellular and stromal explosion along with reduced cell death and growth factor deprivation, and such other factors. Esophageal cancer is cancer arising from the esophagus which is the food pipe connecting the throat and the stomach. Symptoms of esophageal cancer include difficulty and in swallowing which causes reduced food intake and weight loss, enlarged lymph nodes, cough which includes blood etc. The two main sub-types of esophageal cancer are esophageal squamous-cell carcinoma which arises from the epithelial cells and esophageal adenocarcinoma which arises from the glandular cells. These two cancers have different primary causes and different rates of prevalence. Esophageal squamous-cell carcinoma is more common in the developing world, and esophageal adenocarcinoma is more common in the developed world. Causes of the squamous-cell carcinoma include tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut while the most common causes of the adenocarcinoma are smoking tobacco, obesity, and acid reflux.


Considering all these factors the market for esophageal cancer is expected to reach $ 1000.1 million by the end of 2023, this market is projected to growing at a CAGR of ~ 8.7 % during 2017-2023.


 Figure 1 Global Esophageal cancer Market by Type, 2016 (% Market Share)


 


 Intended Audience



  • Global Esophageal cancer solutions providers, manufacturers & suppliers

  • Research and development (R&D) companies

  • Market research and consulting service providers

  • Academic institutes and universities


Key players of Global Esophageal cancer Market: Key players profiled in the report are Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co. and others. Segments: The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other. Regional Analysis US accounts for the maximum market share due to favorable reimbursement scenario and greater expenditure on healthcare. Europe is the second largest market due to large disposable income and rising awareness. Asia pacific region will be the fastest region because of large unmet needs which will be led by China and India. The Middle East and Africa market will be led by the gulf nations particularly Saudi Arabia and UAE. The poor regions of Africa is expected to be a laggard due to poor economic and political conditions.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 1000.1 million
  CAGR   2017-2023: 8.7 %
  Base Year   2019
  Forecast Period   2027`
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   By Type, Phases, Treatment
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Amgen, Eli Lilly and Company, F. Hoffmann-La Roche, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, GlaxoSmithKline Plc., Novartis AG, Johnson & Johnson, Gilead Sciences, Merck & Co.
  Key Market Opportunities   Favorable reimbursement scenario and greater expenditure on healthcare In US
  Key Market Drivers   disordered and deregulated cellular and stromal explosion along with reduced cell death


1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL ESOPHAGEAL CANCER MARKET, BY TYPE

5.1 ESOPHAGEAL SQUAMOUS-CELL CARCINOMA, ,

5.2 ESOPHAGEAL ADENOCARCINOMA

5.3 OTHERS

6 GLOBAL ESOPHAGEAL CANCER MARKET, BY PHASES

6.1 PHASE I

6.2 PHASES II

6.3 PHASES III

7 GLOBAL ESOPHAGEAL CANCER MARKET, BY TREATMENT

7.1 SURGERY

7.1.1 CHEMOTHERAPY AND RADIOTHERAPY

7.1.2 OTHER

8. GLOBAL ESOPHAGEAL CANCER MARKET, BY REGION

8.1 NORTH AMERICA

8.1.1 INTRODUCTION

8.2 EUROPE

8.2.1 INTRODUCTION

8.3 ASIA-PACIFIC

8.3.1 INTRODUCTION

8.4 MIDDLE EAST & AFRICA

8.4.1 INTRODUCTION

9. COMPETITIVE LANDSCAPE

9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

9.1.1 STRATEGIC PARTNERSHIP

9.1.2 MERGER & ACQUISITION

10 COMPANY PROFILE

10.1 AMGEN

10.1.1 OVERVIEW

10.1.2 PRODUCT OVERVIEW

10.1.3 FINANCIALS

10.1.4 KEY DEVELOPMENTS

10.2 ELI LILLY AND COMPANY,

10.2.1 OVERVIEW

10.2.2 PRODUCT OVERVIEW

10.2.3 FINANCIALS

10.2.4 KEY DEVELOPMENTS

10.3 F. HOFFMANN-LA ROCHE

10.3.1 OVERVIEW

10.3.2 PRODUCT OVERVIEW

10.3.3 FINANCIALS

10.3.4 KEY DEVELOPMENT

10.4 BRISTOL-MYERS

10.4.1 OVERVIEW

10.4.2 PRODUCT OVERVIEW

10.4.3 FINANCIALS

10.4.4 KEY DEVELOPMENTS

10.5 SQUIBB COMPANY

10.5.1 OVERVIEW

10.5.2 PRODUCT OVERVIEW

10.5.3 FINANCIALS

10.5.4 KEY DEVELOPMENTS

10.6 BOEHRINGER INGELHEIM GMBH

10.6.1 OVERVIEW

10.6.2 PRODUCT OVERVIEW

10.6.3 FINANCIALS

10.6.4 KEY DEVELOPMENTS

10.7 BRISTOL-MYERS SQUIBB

10.7.1 OVERVIEW

10.7.2 PRODUCT OVERVIEW

10.7.3 FINANCIALS

10.7.4 KEY DEVELOPMENTS

10.8 GLAXOSMITHKLINE PLC.

10.8.1 OVERVIEW

10.8.2 PRODUCT OVERVIEW

10.8.3 FINANCIALS

10.8.4 KEY DEVELOPMENTS

10.9 NOVARTIS AG

10.9.1 OVERVIEW

10.9.2 PRODUCT OVERVIEW

10.9.3 FINANCIALS

10.9.4 KEY DEVELOPMENTS

10.10 JOHNSON & JOHNSON

10.10.1 OVERVIEW

10.10.2 PRODUCT OVERVIEW

10.10.3 FINANCIALS

10.10.4 KEY DEVELOPMENTS

10.11 GILEAD SCIENCES

10.11.1 OVERVIEW

10.11.2 PRODUCT OVERVIEW

10.11.3 FINANCIALS

10.11.4 KEY DEVELOPMENTS

10.12 MERCK & CO.

10.12.1 OVERVIEW

10.12.2 PRODUCT OVERVIEW

10.12.3 FINANCIALS

10.12.4 KEY DEVELOPMENTS

10.13 OTHERS

11 CONCLUSION

11.1 KEY FINDINGS

11.1.1 FROM CEO’S VIEWPOINT

11.1.2 UNMET NEEDS OF THE MARKET

11.2 KEY COMPANIES TO WATCH

11.3 PREDICTION OF ESOPHAGEAL CANCER Solutions INDUSTRY

12 APPENDIX